Podcasts about Eli Lilly

Jim and Jeff discuss this healthcare stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Ireland has become a major base for US pharma companies, including Pfizer, Eli Lilly and Johnson & Johnson. That's bolstered the economies of individual towns and played a role in the country's massive budget surplus. Now, US President Donald Trump's tariff threats are bringing a dose of uncertainty. The FT's Ireland correspondent Jude Webber traveled to the town where the world's supply of Botox is produced to see what impact potential pharmaceutical tariffs might have on the country. Clips from WKYC, The Journal, Bloomberg- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Trump tariffs bring furrowed brows to Ireland's Botox townTrump's tariffs threaten Ireland's pharma fortuneIreland's luxury problem: what to do with its €8.6bn surplus- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Jude Webber on X (@jude_webber), or on Bluesky (@judewebber.bsky.social). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Listen as Gaining Health host, Karli Burridge, reflects on the OMA Annual Conference with Sam and Joe!Petition to keep Zepbound on formulary:  https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationSandra Christensen is board-certified as a family nurse practitioner and holds the Certificate of Advanced Education in Obesity Medicine from the Obesity Medicine Association. She is the founder and Chief Clinical Officer of Integrative Medical Weight Management in Seattle, Washington, and has specialized in obesity management since 2005. She is a Master Fellow of the Obesity Medicine Association and a Fellow of the American Association of Nurse Practitioners. She serves on the Board of Trustees for the Obesity Medicine Association and is the President of the Washington Obesity Society.  She authored the book, “A Clinician's Guide to Discussing Obesity with Patients” published by Springer, and was named the 2022 Obesity Medicine Association Clinician of the Year.The Washington Obesity SocietyIntegrative Medical Weight Managementhttps://www.linkedin.com/in/sandra-christensen/Joseph Zucchi (pronounced Zoo-key) is a board-certified Physician Assistant and Personal Trainer who serves as the Clinical Supervisor of Transition Medical Weight Loss in Salem, New Hampshire. With over a decade of experience in obesity medicine, Joe leads a multidisciplinary team dedicated to helping patients achieve sustainable weight loss and improved health. He has worked with over 2,000 patients to collectively lose more than 40,000 pounds. Joe integrates fitness, nutrition, and medical interventions to provide comprehensive, patient-centered care.  His work has been recognized through multiple accolades, including leading Transition Medical Weight Loss to win awards for best weight loss center in NH. He has written articles and has shared his expertise on obesity care and weight-loss treatments in outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity. Joe also is a speaker for Eli Lilly and educates other providers about Zepbound and obesity medicine. https://www.linkedin.com/in/josephzucchi/https://x.com/JPZfitnesshttps://transitionsalem.com/Support the showThe Gaining Health Podcast will release a new episode monthly, every second or third Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer a Roadmap to starting an obesity program or practice, pre-recorded Master Classes, digital resources including patient education materials and office forms, and much more! Check out our resources on our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

We all know the big economic stories of the year: the trade war, the tariffs. But there's another — even bigger? — story that hasn't been getting the same attention: the Ozempicification of our diets, our bodies and our economy. On this week's TLDR, we take a look at the transformation underway. Plus, economic indicators are telling one story about a potential recession; the headlines are telling another. Which one is right? And, why does it feel like everyone's drinking less alcohol? This episode was hosted by Devin Friedman, business reporter Sarah Rieger and former hedgefunder Matthew Karasz, with an appearance by Armine Yanizyan, Atkinson Fellow on the Future of Workers. Follow us on other platforms, or subscribe to our weekly newsletter: linkin.bio/tldrThe TLDR Podcast is offered by Wealthsimple Media Inc. and is for informational purposes only. The content in the TLDR Podcast is not investment advice, a recommendation to buy or sell assets or securities, and does not represent the views of Wealthsimple Financial Corp or any of its other subsidiaries or affiliates. Wealthsimple Media Inc. does not endorse any third-party views referenced in this content. More information at wealthsimple.com/tldr.

PRWeek toasted the best international work last week at the PRWeek Global Awards in London. Here's a special behind-the-scenes look at the show with Andy Pharoah, VP of corporate affairs and sustainability at Mars and chair of judges for the awards program. Weber Shandwick was the big winner, taking home six awards from the Jumeirah Carlton Tower, in the heart of Knightsbridge, London.Plus, here's a recap of the biggest marketing and communications news of the week, including Adam Collins stepping down from the top comms job at Molson Coors, major hires at Eli Lilly and Company and Jeep and a tribute to Al Tortorella, a key figure in Tylenol's 1982 crisis response.  Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek

I avsnitt 172 av Hälsoveckan by Tyngre diskuterar Jacob och Erik ny data från Eli Lilly om har jämfört deras fetmamedicin Mounjaro mot Novo Nordisk medicin Wegovy, ofta också kallad Ozempic. Det här är den första studien där medicinerna jämförs direkt mot varandra och resultatet visade på en klar fördel för Mounjaro. Erik var under förra veckan också på en stor fetmakonferens där han fick höra om fler resultat från studien som inte fanns med i den publicerade artikeln. På Hälsoveckan by Tyngres instagram kan du hitta bilder relaterat till detta och tidigare avsnitt. Hålltider (00:00:00) Introsnack kring Nyhetsmorgon och fetmakonferenser (00:08:14) Surmount 5 - Mounjaro vs Wegovy (Ozempic) (00:36:50) Outro - GBs nya policy om max 250 kalorier per glass

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

On this week's Inside Indiana Business with Gerry Dick, we continue our “Business at the Brickyard” series from the newly renovated Indianapolis Motor Speedway Museum. The $60 million overhaul is already drawing crowds and boosting memberships, with new interactive exhibits, STEM learning opportunities and a major spotlight on Roger Penske's legacy. Penske Entertainment's Allison Melangton joins Gerry to discuss how IndyCar is strengthening its connection to fans across Indiana — from porch parties and statewide fan fests to collaborations with the arts community. Also in this episode: Big sales at the State Fairgrounds: Mecum Auctions wraps up nine days of bidding with more than 3,000 collector cars and over $100 million in transactions. Roche ramps up in Indy: The company will invest $550 million in its diagnostics campus and bring hundreds of jobs to the city. Slate Auto chooses Warsaw: The electric vehicle startup is repurposing a former printing facility to build affordable EVs, with production starting in 2026. “100 Days to Indy” returns: The hit docuseries gives viewers a behind-the-scenes look at IndyCar stars and their lives off the track. Sam Schmidt marks 25 years: The racing legend expands his impact through the Driven NeuroRecovery Center in Carmel, offering new hope to people with spinal cord injuries. Higher ed investments: Goshen College opens a $21 million nursing training center, and Eli Lilly teams up with Purdue for a $250 million research collaboration. Trackside eats: Yelp's Brittany Smith shares five fan-favorite restaurants near Indiana racetracks, including stops in Speedway, Kokomo and Hobart. As the Indy 500 approaches, we spotlight the people, companies and communities fueling Indiana's motorsports economy.

In this insightful Market Mondays clip, Rashad Bilal, Ian Dunlap, and Troy Millings break down two of the week's biggest financial headlines that could shake up the markets: President Trump's executive order to lower prescription drug prices and Amazon's strategic acquisition of AMD shares. First, the hosts dive deep into the possible long-term impacts of Trump's new executive order aiming to slash prescription drug costs across the board. They discuss the potential winners—everyday consumers in need of lower medication costs—and the possible losers, notably major pharmaceutical companies that may see profit margins squeezed. The conversation covers how this move could spur much-needed innovation within the healthcare sector, but also draws attention to challenges such as lobbying pressure and lengthy litigation. What does this mean for healthcare stocks like Pfizer, Eli Lilly, Novo Nordisk, Johnson & Johnson, CVS, Amgen, and more? The hosts lay out possible outcomes and the bigger economic picture, including references to Mark Cuban's earlier ideas about drug pricing and fair access.Next up, the crew unpacks the real story behind Amazon's much-discussed “purchase” of $84 million in AMD shares. Is this a direct investment or the result of AMD's acquisition of ZT Group International—where Amazon already had stakes? They clarify the technical details and examine how this plays into Amazon's push for self-reliance in AI infrastructure and chip development, following in the footsteps of giants like Apple making their own chips. The discussion also touches on how this integration of hardware and internal resources could position Amazon for even more dominance in the AI race and tech industry at large.Throughout the clip, Rashad, Ian, and Troy provide honest takes on market strategies, investment insights, and the political chess game playing out in real time. From healthcare innovation to tech self-sufficiency, this conversation is a must-watch for investors, entrepreneurs, and anyone wanting to stay ahead of the curve on Wall Street.Don't forget to like, comment, and subscribe for more in-depth market analysis and actionable insights!#MarketMoves #PrescriptionDrugs #HealthcareStocks #TrumpNews #Amazon #AMD #TechStocks #AI #Investing #StockMarket #Finance #BusinessNews #MarkCuban #Pharma #EliLilly #Pfizer #JohnsonAndJohnson #Pharmaceuticals #Innovation #BusinessAnalysis #AmazonPrime #WallStreet #FinancialNewsSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Tenemos en esta ocasión un capítulo especial. Nos adentramos en la historia de la diabetes, una enfermedad que pasó de ser un misterio en la antigüedad a convertirse en un reto global en el siglo XXI. Comprenderla es vital para todos, no solo por su impacto en millones de personas, sino porque revela cómo nuestros hábitos, la alimentación y situaciones sociales influyen directamente en nuestra salud y la de las personas que nos rodean. Conocer la diabetes es entender cómo vivimos y qué podemos cambiar para cuidarnos mejor. Notas del episodio: Este episodio fue patrocinado por Eli Lilly, A Medicine Company El origen de la palabra diabetes Historia de la diabetes El descubrimiento de la insulina Herramientas para conocer tu riesgo de Diabetes Datos de la ONU sobre las diabetes Y aquí les dejamos la página de la Asociación Colombiana de Diabetes  ¡Síguenos en nuestras redes sociales! Facebook: / dianauribe.fm Instagram: https://www.instagram.com/dianauribe.fm/ T witter: https://twitter.com/dianauribe.fm?lang=es Pagina web: https://www.dianauribe.fm TikTok: https://www.tiktok.com/@dianauribe.fm?is_from_webapp=1&sender_device=pc LinkedIn: https://www.linkedin.com/in/diana-uribe-/?originalSubdomain=co  

Cramer breaks down why he ‘likes' this pharmaceutical stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Mark Zuckerberg zal geen fijne dag hebben. Die wordt namelijk ingehaald door zijn grote concurrent, TikTok. Moederbedrijf Bytedance ziet de omzet met 20 procent stijgen, ondanks de pogingen van de VS om TikTok op zwart te zetten. Daardoor zou Bytedance eind dit jaar even groot zijn als Zuckerberg's Meta. Christine Lagarde schreef al drie keer geschiedenis: als eerste vrouwelijke financiënminister in Frankrijk, als eerste vrouw die het IMF leidde, en als eerste vrouwelijke baas van de Europese Centrale Bank. Maar daar kan een vierde bladzijde bijkomen. Volgens Bloomberg maakt ze namelijk ook goede kans op het stoeltje van Klaus Schwab bij het World Economic Forum. Gaat ze daarvoor vervroegd vertrekken bij de ECB? Verder gaat het over Novo Nordisk. Beleggers zijn in de war, want de topman vertrekt opeens. Vermoedelijke reden: de farmaceut verliest de competitie om afvalmedicatie van concurrent Eli Lilly. En dat raakt de prijs van het aandeel te hard. Maar de vraag blijft of het wegsturen van de ceo dat gaat oplossen. Je hoort ook wat er aan de hand is bij Coinbase. Het cryptoplatform krijgt twee klappen te verwerken. Iemand perst ze af, maar de toezichthouder denkt ook dat Coinbase zelf beleggers uitperst. En we blikken terug op de week van Donald Trump. Zijn regering sloot plotseling een tijdelijke deal met China. En zelf zat hij ook niet stil, want hij wist honderden miljarden dollars los te peuteren in het Midden Oosten.See omnystudio.com/listener for privacy information.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

Synopsis: What does bold biotech leadership look like in 2025? In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes. Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon's IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials. They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science. Biography: Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon's Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company's Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners. Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy. Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

This 4-in-1 compilation episode focuses on a persistent disconnect between capital and capability: women are founding businesses at record rates and leading high-performing funds, yet the capital rarely follows.In other words, women are underrepresented both in receiving and managing capital.Today's episode is about those pushing back against that trend – women-led investment managers and those intentionally channeling capital into women-led businesses.Here are the featured guests:Sharon Vosmek, CEO of Astia & Managing Partner of the Astia FundSharon Vosmek doesn't see gender equity in venture as a social goal – she sees it as a market inefficiency. With just 2–3% of VC funding going to women CEOs, she argues the system consistently overlooks high-potential founders. At Astia, she's investing in women-led startups with strong early traction, particularly in underserved sectors like women's health. She also challenges the informal, male-dominated networks – boardrooms, golf courses – where most deals are still made.Full episode Dr. Tara Bishop, Founder and Managing Director of Black Opal VenturesTara co-founded Black Opal Ventures to invest where healthcare and technology collide – and where traditional VC often misses.She and her partner, Eileen Tanghal, raised $63 million from institutional investors like Eli Lilly and JP Morgan, becoming one of the rare female- and minority-led funds in venture. Their portfolio reflects that identity: women-led companies, underserved markets, and problems overlooked by legacy capital.Full episode Tammy Newmark, CEO and Managing Partner of EcoEnterprises FundTammy leads EcoEnterprises Fund, a women-run investment firm focused on nature-positive businesses across Latin America. For over two decades, she's backed companies in sustainable agriculture, ecotourism, and agroforestry – many led by women and rooted in rural or Indigenous communities.Gender equity isn't the fund's focus, but it runs through the portfolio: in leadership teams, supply chains, and daily operations. About half of their investments meet 2X Challenge criteria – not because it's the mandate, but because that's who's doing the work.With $150 million under management, the fund combines financial discipline with long-term environmental and social goals.Full episode Stephanie Cohn Rupp, CEO of Veris Wealth PartnersStephanie runs Veris Wealth Partners, one of the few wealth management firms built from the ground up to do just one thing: impact. With $2.3 billion under management and offices across the U.S., Veris has been majority women-led and women-owned since its founding in 2007.It's built entirely around impact – certified B Corp, net zero, and intentionally conflict-free – and applies that lens across every asset class, with a deep focus on racial equity, climate, gender, and community wealth.For Stephanie, this isn't about doing impact. It's about being built for it.Full episode—The SRI 360° Podcast is focused exclusively on sustainable & responsible investing.—Connect with SRI360°:Sign up for the free weekly email update.Visit the SRI360° PODCAST.Visit the SRI360° WEBSITE.Follow SRI360° on X.Follow SRI360° on FACEBOOK.

Afslankmedicijnen vliegen als warme broodjes over de toonbank. In een farmaceutische afvalrace strijden Eli Lilly en Novo Nordisk om het beste medicijn. Sinds kort lijkt Eli Lilly de beste kaarten in handen te hebben. In hoeverre helpen die medicijnen nou echt overgewicht de wereld uit? En hoe afhankelijk is het bedrijf inmiddels geworden van het afslankmiddel Mounjaro? Marco Frenken, country manager van Eli Lilly Nederland is te gast in BNR Zakendoen. Macro met Mujagić/Boot Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić. Ook altijd terug te vinden als je een aflevering gemist hebt. Blik op de wereld Wat speelt zich vandaag af op het wereldtoneel? Het laatste nieuws uit bijvoorbeeld Oekraïne, het Midden-Oosten, de Verenigde Staten of Brussel hoor je iedere werkdag om 12.10 van onze vaste experts en eigen redacteuren en verslaggevers. Ook los te vinden als podcast. Lobbypanel Culturele organisaties moeten langer subsidie krijgen. En kan de premie verplichte verzekering voor zelfstandigen tegen arbeidsongeschiktheid omlaag? Dat en meer bespreken we in het lobbypanel met: - Nora van Elferen, partner bij EPPA - Debbie de Wagenaar, reputatiemanager voor bedrijven Luister l Lobbypanel | Zakenlunch Elke dag, tijdens de lunch, geniet je mee van het laatste zakelijke nieuws, actuele informatie over de financiële markten en ander economische actualiteiten. Op een ontspannen manier word je als luisteraar bijgepraat over alles wat er speelt in de wereld van het bedrijfsleven en de beurs. En altijd terug te vinden als podcast, mocht je de lunch gemist hebben. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 11:00 tot 13:30 uur. Je kunt de redactie bereiken via e-mail. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

Kenzie details the complex murder of an Eli Lilly employee. Chicago’s best morning radio show now has a podcast! Don’t forget to rate, review, and subscribe wherever you listen to podcasts and remember that the conversation always lives on the Q101 Facebook page. Brian & Kenzie are live every morning from 6a-10a on Q101. Subscribe to our channel HERE: https://www.youtube.com/@Q101 Like Q101 on Facebook HERE: https://www.facebook.com/q101chicago Follow Q101 on Twitter HERE: https://twitter.com/Q101Chicago Follow Q101 on Instagram HERE: https://www.instagram.com/q101chicago/?hl=en Follow Q101 on TikTok HERE: https://www.tiktok.com/@q101chicago?lang=enSee omnystudio.com/listener for privacy information.

The Indiana Pacers are one game away from advancing to the NBA Eastern Conference Finals. Eli Lilly and Company announce an expanded partnership with Purdue University. An Indianapolis Public Schools district school will convert to a charter school. The Trump Administration terminates federal funding that supports artists across Indiana. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Drew Daudelin, Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

Progress continues to...progress on the Eli Lilly site on the north side of town. On Episode 212 of the #LovinLebanon Podcast, we check in with Todd Dando and Jeff Wagner from Fluor Corporation to get an update on the construction process. Roughly two thousand workers are on-site right now, but that number is about to increase. Jeff and Todd share the efforts in place to meet upcoming challenges.

Er der strategier, der på langt sigt kan levere pæne afkast på trods af volatile markeder, som dem vi har set i år? Ja, mener dagens gæst i Millionærklubben, Jens Løgstrup, der de seneste 25 år har præsteret et bemærkelsesværdigt højt afkast ved at følge sin helt egen metode.I studiet tager tekniske analytiker Lars Persson lytterne med ud på dagens marked og ser på nyheder fra Novos ærkerival, Eli Lilly. Vært: Bodil Johanne Gantzel.See omnystudio.com/listener for privacy information.

Parkinson's: Diagnosis and Treatment Evaluation and Credit:  https://www.surveymonkey.com/r/medchat78 Target Audience             This activity is targeted toward primary care physicians and advanced providers. Statement of Need This podcast will provide an overview of the diagnosis and management of Parkinson's disease including screening guidelines to improve early recognition. In that early symptoms of Parkinson's disease can mimic other conditions, for early recognition a review of this will be highlighted. The goal of this podcast is to provide tools for early recognition and management to maintain a patient's quality of life. According to the Parkinson's Foundation, there are approximately 90,000 people in the U.S. diagnosed with Parkinson's each year, which represents significant increase.  Objectives  Define Parkinson's disease and highlight its prevalence. Explain the signs and symptoms of Parkinson's disease, including the moto and non-motor manifestations. Outline the diagnostic criteria for Parkinson's disease, including clinical evaluations, neurological exams and applicable testing. Discuss the management of Parkinson's disease symptoms, addressing pharmacological treatments, surgical options and multidisciplinary team strategies to optimize patient care. ModeratorGregory E. Cooper, M.D., Ph.D. Neurologist Chief of Adult Neurology and Director of the Memory Center Norton Neuroscience Institute Louisville, Kentucky SpeakerJason L. Crowell, M.D. Neurologist and Movement Disorders Specialist Norton Neuroscience Institute Louisville, Kentucky  Moderator and Planner Disclosures  The moderator, Gregory E. Cooper, M.D., Ph.D, discloses relevant financial relationships with Eli Lilly and Eisai as a principal investigator. The planners of this activity do not have any relevant financial relationships with ineligible companies to disclose.   Speaker DisclosureThe speaker, Jason L. Cromwell, M.D. discloses a relevant financial relationship with the ineligible company AbbVie as a consultant and CND Life Services in research.  All relevant financial relationships have been successfully mitigated. Commercial Support There was no commercial support for this activity.    Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing CreditsNorton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.50 ANCC CE contact hours.  In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.  For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Resources for Additional Study/References  Perspectives of People At-Risk on Parkinson's Prevention Research https://pubmed.ncbi.nlm.nih.gov/38489198/ Risk of Parkinson Disease Among Adults With vs Without Posttraumatic Stress Disorder https://pubmed.ncbi.nlm.nih.gov/35925604/ Date of Original Release | May 2025; Information is current as of the time of recording.  Course Termination Date | May 2028 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope. Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.  

In this edition of Inside INdiana Business with Gary Dick, the business of motorsports is in full throttle as Business at the Brickyard continues. From Gasoline Alley to global headquarters for brands, we explore why Indiana is one of the top three motorsports hubs in the world. Veteran executive Rollie Helmling breaks down the industry's $1 billion impact, and why Indy's brand is key to future growth. Plus: • The hidden economic engine inside IndyCar: $100 million in cars, $350K chassis, $1M engines, and elite STEM careers. • An Italian racing school plants roots in Indianapolis, training the next generation of mechanics and engineers—including a Hamilton Southeastern grad. • IMS revs up sustainability: composting, recycling, and new initiatives to reduce waste from 300,000 race day fans. • Eli Lilly breaks ground on its $4.5 billion Lebanon Medicine Foundry, creating 400 jobs in the LEAP Innovation District. • Aer Lingus launches a transatlantic connection from Indianapolis to Dublin. • Anne Frank trees grown in Jackson County head to schools across the U.S. • Kyle Cummins keeps Hoosier dirt track tradition alive with a sprint car career rooted in small-town Indiana grit. The Month of May is just heating up. We'll be at the Indianapolis Motor Speedway all month with exclusive coverage of Indiana's most iconic economic driver.

Eli Lilly has plastered a 'fat tax' on the Canadian market for their weight loss drug. Dr. Yoni Freedhoff joins the program with his reaction. Then, Dr. Dworkin opens the phone lines and reads your texts.

Eli Lilly & Co. is making a big investment into a further partnership with Purdue University to better research and make medicines. And Goshen College is opening a new nursing building, which official hopes can double or triple the program's size.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über die Magie der Mausaktie Disney, Insolvenz einer Diät-Ikone und den stoischen Kurs der Fed. Außerdem geht es um Alphabet, Nvidia, Uber, Charles River Laboratories, Hensoldt, Fresenius, Vonovia, Carl Zeiss Meditec, Eli Lilly, Novo Nordisk, WeightWatchers, Volkswagen, Mercedes, BMW, Ferrari, Nvidia, Meta Platforms, Microsoft, Altria, Saudi-Aramco, AppLovin, ConocoPhillips, CNOOC, Investor AB, Arista Networks, Visa, Blackstone, KKR, Pinduoduo, Investor AB, Hermès, Münchener Rück, Allianz, Deutsche Telekom, SAP, MicroStrategy und Vertex Pharmaceuticals. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk predicts a brighter future for Wegovy with the end of the semaglutide shortage, but analysts remain skeptical as Eli Lilly's Zepbound gains ground in sales. The new HHS vaccine requirement has raised questions about its true intentions, with leading vaccine physician Paul Offit criticizing the lack of clarity. Meanwhile, pharmaceutical imports from Ireland are on the rise, biotech stocks fell after Vinay Prasad was named to succeed Marks at CBER, and Lotte Biologics' ADC facility in Syracuse offers end-to-end services for antibody manufacturing. CRISPR's Casgevy is gaining traction with more gene therapy proof of concept expected in 2025, impacting M&A and IPOs in the biotech industry. Summit Pharmaceuticals is nearing the first global phase III data for Keytruda, set to lose exclusivity in 2028 and potentially face competition from biosimilars. A report suggests that low-price drug nations are benefiting from US innovation, undervaluing innovative medicines by 90%. VC financing in biopharma declined by 20% in Q1, but megarounds kept the median deal size high. M&A and IPOs faced challenges due to policy issues, leading to an increase in licensing deals. Novo vows to improve market access for Wegovy, while Trump orders FDA to ease US plant expansion and increase inspections of foreign facilities. BMS pledges a $40 billion investment in the US, Novartis makes M&A moves, and Lilly remains unfazed by CVS's decision to side with Novo in the obesity market battle. Some drugmakers are stockpiling products in the US amid Trump's trade war. NGM terminates half of its staff as its lead asset moves through a registrational study. Job opportunities in clinical quality assurance audit, RBQM central statistical monitoring, and field medical capabilities are available.

Networking is an integral part of our lives, both professional and personal.  I welcome back Nancie McDonnell Ruder, an extraordinary business woman from the Warrior community, to discuss the skills of networking and connecting with others.  We discuss how we can cultivate the best mindset and what tactical tips, inspiration and perspectives can we learn that will help us to connect and network better.  Nancie McDonnell Ruder is an executive coach, leadership advisor and marketing consultant with decades of experience in marketing strategy, training, branding, and consumer research. She has a strong track record of driving accelerated growth for organizations by aligning their marketing strategies closely with customer expectations and preferences.  Nancie began her professional career with the Leo Burnett Company in Chicago, Illinois, where she served clients such as Procter & Gamble, Eli Lilly and The Gap, and spearheaded global new business efforts, resulting in 14 cross market new business wins.  Since launching Noetic Consultants in 2002, Nancie has provided strategic guidance to clients large and small, including: 7-Eleven, Discovery Channel, Georgetown University, NIKE, Vail Resorts, Samsung Electronics, SC Johnson, Mayo Clinic, and the Walt Disney Company. She is the creator of the Noetic Brand Health Diagnostic™ and the Noetic Art & Science Assessment™.  In addition to her consulting work, Nancie is a respected author and sought-after speaker in the marketing and leadership space. Her engaging presentations draw from her extensive experience, providing actionable takeaways that help organizations and individuals thrive in today's competitive business landscape.(3:42)  Why did we decide to partner and discuss networking?  (6:05) The word “networking”, how do we define it?  (12:40) How can we integrate networking into our personal and professional lives?  (14:37) Why networking matters? What are some of the barriers we experience related to networking?  (18:32) What are some of the fears we experience when we don't exercise our “networking muscles” regularly?  (20:55) Nancie discusses the many ways we can use networking in our lives.  (23:05) We talk about the concept of “Give and Take” from Adam Grant.  (28:30) We discuss concepts of “helping others to succeed first”, how we are “you're only as good as your network” and “you can't get there alone and you don't want to”.  (32:20) Thinking of interactions with others as an “ask, offer and acknowledge”.  (35:54) Where can someone begin on the path to successful networking?  How can we learn good habits from the beginning?  (45:08) Tactical things you can do before networking with others.  (48:26) Do's and Don'ts when networking  (55:25) Let's wrap up the highlights of our conversation around being connected and networking.  (56:47) We ask the community to take away an important point from our conversation.Connect with Nancie McDonnell Ruder https://www.linkedin.com/in/nancieatnoetic/ https://noetic.io/   Subscribe: Warriors At Work Podcasts Website: https://jeaniecoomber.com Facebook: https://www.facebook.com/groups/986666321719033/ Instagram: https://www.instagram.com/jeanie_coomber/ Twitter: https://twitter.com/jeanie_coomber LinkedIn: https://www.linkedin.com/in/jeanie-coomber-90973b4/ YouTube: https://www.youtube.com/channel/UCbMZ2HyNNyPoeCSqKClBC_w

Indianapolis-based pharmaceutical company Eli Lilly broke ground Tuesday on its $4.5 billion facility in Lebanon. It may become more difficult to board commercial flights or enter some federal buildings beginning Wednesday without what's called a Real ID. If you're a parent in the city, your voice could help shape the future of Indianapolis Public Schools. Half of all Americans have been breathing in dangerous levels of air pollution between 2021 and 2023. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Drew Daudelin, Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

En Capital Intereconomía, Miguel Méndez, analista independiente, comenta la situación de los mercados financieros y resuelve las dudas de nuestros oyentes. La sesión del día de hoy comienza en positivo. El rebote del SP & 500 está por encima del 10% y sobre cómo se puede comportar el mercado en el futuro, Méndez cuenta que “Creo que el rebote va a continuar, esto es solo el aperitivo”. En contraste, la compañía farmacéutica, Novo Nordisk, se mantiene en caída. Méndez tiene claro en qué compañía farmacéutica centrarse, y comenta que “si tuviera que quedarme con alguna farmacéutica sería Eli Lilly”. Por otro lado, entre los cirptoactivos, el experto financiero valora el bitcoin, que está ofreciendo un buen rendimiento. Por el contrario, asegura que “Ethereum está más débil”.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über zwei Gipfelstürmer im Dax, das 20.000-Punkte-Comeback des Nasdaq und was diese Woche sonst noch wichtig wird. Außerdem geht es um Rheinmetall, Siemens, Siemens Energy, Münchener Rück, RWE, BASF, Aixtron, Berkshire Hathaway, Novo Nordisk, Eli Lilly, Pfizer, Merck KGaA, Viking Therapeutics, Gilead, Regulus Therapeutics, SpringWorks Therapeutics, Nuvalent, Legend Biotech, Dexcom, Arcellx, Blueprint Medicines, Roche und Johnson&Johnson. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode, Scott Becker discusses sharp market declines for Coca-Cola, Eli Lilly, and Becton Dickinson.

Scott Wapner and the Investment Committee debate the rebound in stocks as the S&P 500 heads for its longest winning streak in 20 years. The experts detail their latest portfolio moves. CNBC Senior Markets Commentator Michael Santoli joins from Omaha with a special Midday Word ahead of Berkshire Hathaway's annual shareholder meeting. Calls of the Day include AutoZone, Roblox, Eli Lilly, Johnson & Johnson, and Quanta Services. NBC Sports host Mike Tirico is live in Churchill Downs ahead of the 151st Kentucky Derby. The Setup is on Ferrari, Zoetis, Elanco Animal Health.Investment Committee Disclosures

In this episode, Scott Becker discusses sharp market declines for Coca-Cola, Eli Lilly, and Becton Dickinson.

Earnings season is in full swing, with Apple and Amazon headlining the action. Deepwater Asset Management's Gene Munster joins to break down the key takeaways from the day's big reports. And Eli Lilly dropping as the drugmaker cuts its profit forecast. Mizuho's Jared Holz digs into the details, and where the pharma space is heading next. Plus, how the markets are setting up ahead of tomorrow's jobs report.  Fast Money Disclaimer

Carl Quintanilla, Jim Cramer and David Faber discussed blowout quarterly results from Microsoft and Meta that sparked a rally inthe tech sector -- as the Dow and S&P 500 aim to extend their respective daily win streaks to eight. The anchors also reacted to Tesla's denial of a report stating the company's board opened a search for a successor to CEO Elon Musk. Also in focus: Eli Lilly and McDonald's join the earnings parade, Softbank CEO Masa Son on China and AI, President Trump's "two dolls" comment on tariffs.

Scott Wapner and the Investment Committee debate where the economy is heading as tariff turmoil sends GDP into the red. The panel take their position on big tech ahead of earnings. Karen Firestone details her latest portfolio moves. Calls of the Day include AppLovin, CoStar, Cheniere, Spotify, and Raymond James. The earnings setup is on Allstate, Eli Lilly, Amgen, Live Nation, and Exxon Mobil. 

Obesity-related stigma is combatted with a bias-free image gallery and people-first language to reduce weight discrimination. In this episode, Jamie Coleman, Vice President of Marketing at Eli Lilly and Company , discusses initiatives to combat obesity-related stigma, focusing on a bias-free image gallery created with the Obesity Action Coalition. She explains obesity as a complex disease, often misunderstood, with media reinforcing stereotypes. The gallery aims to humanize obesity and improve care. Jamie highlights the impact of weight bias on access to care and urges the use of people-first language to reduce stigma, equating weight discrimination to a human rights issue.  Tune in to gain valuable insights into how these efforts are changing the landscape of obesity care! Resources: Connect with and follow Jamie Coleman on LinkedIn. Follow Eli Lilly and Company on LinkedIn and visit their website.  Learn about the Stop Weight Bias campaign. Check out the OAC Bias-Free Image Gallery.

Rarely is one of our shows as intricately fascinating and self-disclosing to our guest and ourselves that we cannot adequately describe all that we covered, all that we learned, and all that we began integrating anew into our knowledge as the interview evolved.   Our guest, physician Juliette Engel, was a captive, slave, and experimental subject controlled by the CIA from early childhood until age sixteen. Acting on her own, she then escaped the CIA/MKUltra house of devil worship — a subject we will let her tell you about in the interview. She began her new life as a college student, and to manage her severe post-traumatic stress, she developed amnesia for her horrendous past. As a therapist and researcher, I know this happens, but it requires a powerful mind like Dr. Engel to accomplish it and ultimately to flourish.   Dr. Engel is part of a growing number of people coming forth about their experiences as victims of CIA experiments, which in part were training her to become a part of what I have decided to call, “the global community of abusers without conscience,” a powerful aspect of the global predators and their unholy empires.   Adding incredible background to her personal testimony, she sent us in advance a document released from the National Security Archive on December 23, 2024. The ominous title is “CIA Behavioral Control Experiments Focus of New Scholarly Collection.”   The CIA documents confirm many of Dr. Engel's memories, which only began to unfold much later, after a life of medical reform work in Russia.   Confirming Our Own Experiences with the Deep State and CIA   One huge confirmation for me and Ginger is how much the CIA was indeed focused on defending and supporting the very kind or torturous and inhuman psychiatric treatments that I began openly opposing in the early 1970s, including lobotomy and other forms of psychosurgery and electroshock (ECT) which I have described as an electrical closed-head lobotomy.   Another insight for me was the similarity between the CIA agents and collaborators, as described in the CIA documents, and the global predators we have described in our book, COVID-19 and the Global Predators: We Are the Prey. This is the same profile we continue to explore in our recent columns about America's four current empires: the Western Global Empire, the Eastern Global Chinese Communist Empire, the Russian Empire, and the Caliphate Muslim Empire.   These predators, across a broad spectrum of activities, are primarily motivated by a lust for power over other human beings. They also desire wealth, but mostly as a tool for gaining power. What drives them is the desire to exert power over as many people as possible within their sphere, whether it is a political party, a criminal cabal or conspiracy, a government agency, a nation, an empire, or a global governance.   If they did not lust for power, they would not succeed in their goal of dominating, controlling, exploiting, enslaving, or killing as many people as possible. They must also possess extreme cunning and shrewdness to be able to manipulate and exploit so many people and to compete for power among so many other violent, cunning people. Probably above all else, they must be masters of conspiracy, able to seduce or intimidate others into helping them pursue their evil aims.   These predators must lack identification with the people within their own family,  group, nation, or empire, because seizing and growing enormous power usually requires, as history demonstrates, killing competitors in their own families and their own inner circles of co-conspirators, as well as millions of their own people, as demonstrated by apex global predators from Alexander “the Great” to Hitler, Stalin, Mao, and the current leaders of Communist China.   These predators must not allow themselves to genuinely love anyone, because such entanglements and feelings would check or inhibit the kind of evil conduct required for fulfilling their primary lust for power. Ultimately, they must not identify with anyone but themselves.   The following excerpts are taken from the vastly important document that our guest, Juliette Engel, MD, first drew to our attention, “CIA Behavior Control Experiments Focus of New Scholarly Collection.”  [The document lacks page numbers, but the excerpts can be located by means of searching the document:]   Excerpt 1 from the CIA Documents   Asked whether the CIA had tried to identify “techniques of producing retrograde amnesia,” Gottlieb said it was something that they “talked about,” but that he could not “remember any specific projects or specific research mounted in response to that question.” Asked if the CIA ever used “psychosurgery research projects,” Gottlieb said his “remembrance is that they did.”   Excerpt 2   The elevation of Allen Dulles to deputy director of central intelligence in 1951 led to an expansion of BLUEBIRD programs under a new name, ARTICHOKE, and under the direction of Gottlieb at TSS. The new program was to include, among other projects, the development of “gas guns” and “poisons,” and experiments to test whether “monotonous sounds,” “concussion,” “electroshock,” and “induced sleep” could be used as a means to gain “hypnotic control of an individual.”[5]   Excerpt 3   Another prominent MKULTRA “cutout” foundation, the Human Ecology Society, was run by Cornell Medical Center neurologist Dr. Harold Wolff, who wrote an early study of communist brainwashing techniques for Allen Dulles and later partnered with the CIA to develop a combination of drugs and sensory deprivation that could be used to erase the human mind. Among the most extreme MKULTRA projects funded through Wolff's group were the infamous “depatterning” experiments conducted by Dr. D. Ewen Cameron at the Allan Memorial Institute, a psychiatric hospital at McGill University in Montreal, Canada. Cameron's methods combined induced sleep, electroshocks, and “psychic driving,” under which drugged subjects were psychologically tortured for weeks or months in an effort to reprogram their minds.   Except 4   While no new techniques had been discovered, presently known mind control techniques described in the attachment include the use of LSD and other drugs, hypnosis, the use of the polygraph, neurosurgery, and electric shock treatments. However, field testing of these techniques has been handicapped by the “inability to provide the medical competence for a final evaluation and for such field testing as the evaluation indicates. Repeated efforts to recruit medical personnel have failed and until recently the CIA Medical Staff has not been in a position to assist.”   Excerpt 5   The response from TSS lists 17 “materials and methods” that the Chemical Division was working to develop, including:   *substances that “promote illogical thinking,” materials that would “render the induction of hypnosis easier” or “enhance its usefulness,” substances that would help individuals to endure “privation, torture and coercion during interrogation” and attempts at ‘brainwashing,'” *“materials and physical methods” to “produce amnesia” and “shock and confusion over extended periods of time,” substances that would “produce physical disablement, including paralysis, *substances that “alter personality structure” or that “produce ‘pure' euphoria with no subsequent let-down,” and a “knockout pill” for use in surreptitious druggings and to produce amnesia, among other things. [Asterisks and bold added]   Excerpt 6   Gibbons was not fully clear on how the CIA obtained LSD, but most of it came from the Eli Lilly & Company, according to this memo, which “apparently makes a gift of it to CIA.”  [bold added. There are many mentions in the report citing Eli Lilly as the source of massive of amounts of LSD which the CIA then inflicted upon Americans, sometimes as experiments and sometimes for financial gain.]   End of Excerpts   In the current release of CIA documents, many well-known government officials and universities are named as supporting and collaborating with MKUltra and other ghastly CIA experiments. Particularly stunning to me, the CIA bought a new wing for the Georgetown University Hospital, in return for which the CIA was given a special “safe house” inside the medical wing where they were free to inflict their wanton will on involuntary experimental subjects with supportive help from the hospital.   One More Step in Facing the Evil Within   These quotes confirm what I had long suspected and had only limited data to confirm — that the CIA and other government agencies are very protective and supportive of psychosurgery (lobotomy) and electroshock treatment (ECT). They want to research and apply these gross methods of damaging the human brain and mind to facilitate interrogation, to erase memories, to change personalities, and to make people more obedient and robotic. They also want them widely used in society to dumb down and render passive as many people as possible on the way to building the global slave state.   During this interview, we began to more deeply appreciate the involvement of the Deep State in psychiatry and psychology and the strength of their opposition to my reform work going back to the early 1970s. My earliest reform efforts focused on these two treatments, psychosurgery and then electroshock, and finally matured into seeing all psychiatric treatment as an assault on the brain and mind.   In various books and scientific articles, Ginger and I have been pointing to federal agencies pushing lobotomy (DOJ, NIMH), pushing electroshock (CIA, FDA), and pushing psychoactive drugs (FDA, CIA, NIMH, NIH, Department of Education, and others.   Our greatest confrontation with federal agencies came during an intense few years when we educated and organized people to shut down a massive U.S. interagency eugenical program to go into the inner cities to identify supposed biological and genetic causes of violence in black children and youth. The goal was ultimately to justify the widespread diagnosing and drugging of these children, including highly remunerative drugs like antidepressants and stimulants. I had already encountered outright racism, with neurosurgeons and psychiatrists advocating in print for the use of psychosurgery to control the leaders of black uprisings in the 1960s and early 1970s.   We completely defeated the massive eugenics project, causing the cancellation of a major conference and many research projects. We authored a book about it, The War Against Children of Color (1994), which addresses numerous Deep State actors such as the CDC, Department of Justice, FBI, NIMH, NIH, DHHS, and PHS, and names many perpetrators. But we had not yet seen the globalist scope of these activities. Here are links to a few articles about our successful efforts to stop the federal eugenics program.   The Role of Psychiatry in Nazi Germany and the U.S. Violence Initiative. This link contains the written introduction and historical video of Dr. Peter Breggin's presentation to Black leaders and community members in Harlem in the early 1990s about the federal government's plans to biologically “prevent violence” by identifying and drugging Black toddlers and children—a plan ultimately stopped due to the Breggins' exposure of the eugenics program. A biomedical programme for urban violence control in the US: the dangers of psychiatric social control; by Peter R Breggin and Ginger Ross Breggin Letter to the Editor, The New York Times by Peter R. Breggin, M.D.: U.S. Hasn't Given Up Linking Genes to Crime.  Excerpt: “Dr. Goodwin estimates that 100,000 children, as young as 5, will be identified for psychiatric interventions. He called the violence initiative the No. 1 funding priority for the Federal mental health establishment in 1994. My organization has since obtained documentation that millions of dollars of Federal funds are being spent on violence initiative research and planning, including studies of both rhesus monkeys and inner-city children. Newly developed psychiatric drugs are being tested for violence prevention in monkey studies, and some psychiatrists are claiming they can be used in humans for the same purpose. It seems inevitable that the violence initiative will involve administering the same drugs to inner-city children. The widespread use of Ritalin to control aggressive children, frequently supported or initiated by public schools, has set a precedent for pharmacological intervention.” Disposable Children in Black Faces: The Violence Initiative as Inner-City Containment Policy; Alfreda A. Sellers-Diamond, UMKC Law Review, 1994. Campaigns Against Racist Federal Programs by the Center for the Study of Psychiatry and Psychology; Peter R. Breggin, Journal of African American Men, 1995. NIH, under fire, freezes grant for conference on genetics and crime; Nature, Vol. 358, 30 July 1992, p357.   It was further hammered home to me in the interview with Dr. Engel that the kinds of individuals who are cunning enough and violent enough to run totalitarian nations and empires have their counterparts running amok within many federal agencies and many other American institutions. And that is the force from within that we are fighting today as we stand up for freedom in America. We must face a former national leadership, and a current Deep State and other institutions riddled with the worst human beings we can imagine and understand — or we will remain vastly hampered in fighting them.     ______   Learn more about Dr. Peter Breggin's work: https://breggin.com/   See more from Dr. Breggin's long history of being a reformer in psychiatry: https://breggin.com/Psychiatry-as-an-Instrument-of-Social-and-Political-Control   Psychiatric Drug Withdrawal, the how-to manual @ https://breggin.com/a-guide-for-prescribers-therapists-patients-and-their-families/   Get a copy of Dr. Breggin's latest book: WHO ARE THE “THEY” - THESE GLOBAL PREDATORS? WHAT ARE THEIR MOTIVES AND THEIR PLANS FOR US? HOW CAN WE DEFEND AGAINST THEM? Covid-19 and the Global Predators: We are the Prey Get a copy: https://www.wearetheprey.com/   “No other book so comprehensively covers the details of COVID-19 criminal conduct as well as its origins in a network of global predators seeking wealth and power at the expense of human freedom and prosperity, under cover of false public health policies.”   ~ Robert F Kennedy, Jr Author of #1 bestseller The Real Anthony Fauci and Founder, Chairman and Chief Legal Counsel for Children's Health Defense.  

Scott Wapner and the Investment Committee discuss whether stocks are poised for a major comeback as we mark the first 100 days for President Trump. Bill Baruch calls in with reaction to Spotify. Josh Brown details his latest portfolio moves. The panel debates the red-hot cyber trade. The Setup is on Eli Lilly and Shake Shack.Investment Committee Disclosures

Want the skinny on the magic pill everyone is talking about? If you've ever considered trying Ozempic or a similar weight loss drug, you're not alone! In this episode, I share the pros and cons of Ozempic, my honest and objective perspective, and my top weight loss tips.The hard truth is that weight loss is difficult! With Eli Lilly's announcement of a phase 3 trial for a cheaper, oral weight loss pill, this topic is hotter than ever. One thing to consider is that a quick fix pill doesn't make you healthier or ensure the weight stays off, whereas doing strength and nutrition work guarantees a healthier tomorrow. When we get down to it, it's not the weight loss itself that's hard, it's the behavior modification that supports a healthy lifestyle that some people struggle with. I share my analysis of the Ozempic results, and the conclusion will surprise you! In particular, the reasons why you are better off without taking a weight loss drug and instead joining my program, the Body Composition Project, where participants lose double their body weight in half the time of what Ozempic clinical trials report. Crazy, right?! I then explain why a mindset shift is essential to long-lasting weight loss, how to improve your insulin sensitivity, and the importance of building muscle to lose fat. Remember, you have the power to change your body composition today. Why wait!Ready for a great night's sleep? Try Beam's best-selling Dream Powder and get up to 40% off for a limited time. Visit shopbeam.com/HOLLYP and use code HOLLYP at checkout.You can get FREE access to my 4-week Strength Without Stress program right now! Thisprogram will help you reduce the systemic inflammation that's caused by overly intense orlengthy workouts. It'll help you build and maintain valuable lean muscle withoutthe fatigue from other programsTo get free access to Strength Without Stress, post a Review wherever you listen. Grab a screenshot of your review before you post it and upload at: https://www.hollyperkins.com/reviewThis is a limited-time offer before it sells for $197–grab it while you can for lifetime access.Be sure to Follow and Subscribe so you'll know exactly when new episodes are available on Tuesdays.Topics coveredThe temptation of effortless weight lossWeight loss IS hard! Weight loss medications work, but at what cost?Why behavior modification is so challengingThree key misunderstandings about weight loss drugsReasons why you're better off without weight loss medicationWhy a mindset shift is key to sustainable weight lossRemember, not eating causes weight loss AND muscle lossResources MentionedResearch on Eli Lilly's oral weight-loss pill shows promising resultsResearch on healthy weight loss maintenanceResearch about understanding a diabetes diagnosisResearch about the effect of semaglutide on overweight adultsResearch summary on the impact of semaglutide on obese adultsResearch on resistance

Scott Wapner and the Investment Committee debate the state of stocks and the moment of truth for mega-cap tech. Calls of the Day include Eli Lilly, UnitedHealth, and Chipotle. Bill Baruch calls in with a new trade ahead of earnings. The Setup is on Visa, AstraZeneca, Sherwin-Williams, and S&P Global.Investment Committee Disclosures

The S and P 500 was relatively unchanged ahead of a packed week for earnings and economic data, Wall Street is also awaiting any progress on trade deal negotiations, Amazon, Apple, Meta Platforms and Microsoft will all release their quarterly reports as will Visa, Coca-Cola, and Eli Lilly

The newly established, so-called Department of Government Efficiency is reportedly freezing healthcare grants. Eli Lilly sues telehealth companies over compounded versions of its popular weight loss drug. And, Walgreens settles a case from the federal government in the ongoing opioid crisis. Those stories and more coming up on today's episode of Gist Healthcare Daily. Hosted on Acast. See acast.com/privacy for more information.

Why did news from a weight-loss drug pill trial boost Eli Lilly? And how are costs in the Medicare business affecting UnitedHealth? Plus, what ambitious goals has Netflix set for itself? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why did news from a weight-loss drug pill trial boost Eli Lilly? And how are costs in the Medicare business affecting UnitedHealth? Plus, what ambitious goals has Netflix set for itself? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Tesla class action lawsuit… Google guilty… Meta is still under fire… Menendez hearing in May… Administration lawsuits abounding… Supreme Court will look at birthright… Message in a Bottle found… NBA / NHL playoffs begin… Lee Corso retiring… Mike Leach talked down from idea… Email: ChewingTheFat@theblaze.com Swimming with Aqua Tots… Who Died Today: Patrick Adiarte 82… Puerto Rico loses power and water… Eli Lilly moving forward with anti-fat pill… Pfizer cancels anti-fat pill?... Seed Oils and Breast Cancer… www.blazetv.com/jeffy Promo code Jeffy… Game Show: What's The Lie? Contestant: Dakota Lally / returning champion… Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Scott Becker shares insights on four major market movers.

'Dying for Sex' creators on supporting breast cancer community; Fyre Festival 2 postponed, organizers announced; Eli Lilly says new data shows promising results for GLP-1 pill Learn more about your ad choices. Visit podcastchoices.com/adchoices